Neddylation Site Modified AAV Vectors for Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy using Adeno-associated virus (AAV) vectors faces significant challenges due to intra-cellular defense mechanisms, particularly proteasome-based degradation during cytoplasmic trafficking, where the role of ubiquitination is well-studied but that of Neddylation, a ubiquitin-like modifier, is unknown, impacting the efficiency of gene transfer, especially in ocular gene therapy.
Innovation Solution
The process involves predicting and modifying Neddylation sites on the AAV VP1 capsid protein sequence by mutating lysine residues to glutamine, creating Neddylation site modified AAV vectors that are targeted for destruction by the cellular proteasomal machinery, enhancing transduction efficiency through site-directed mutagenesis and purification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AAV vectors are used for gene therapy, then gene transfer efficiency is improved, but transduction efficiency is reduced due to proteasome-based degradation
Solution Approach 1:
The patent applies parameter changes by mutating specific amino acid residues (lysine to glutamine substitutions) at predicted Neddylation sites on the AAV capsid proteins (VP1, VP2, VP3). This chemical modification of the capsid structure prevents Neddylation-mediated proteasomal degradation, thereby resolving the contradiction between maintaining gene transfer capability and improving transduction efficiency by reducing vector degradation in the cytoplasm
Solution Approach 2:
The patent converts the harmful effect of Neddylation (which leads to proteasomal degradation and reduced transduction) into a beneficial outcome. By predicting Neddylation sites using bioinformatics tools and mutating these sites, the invention transforms the degradation pathway into a controlled modification that actually enhances vector stability and transduction efficiency while preserving the gene therapy function
2Productivity
If Neddylation sites are mutated to prevent degradation, then transduction efficiency is improved, but vector structure is modified
Solution Approach 1:
The patent applies local quality by making targeted, site-specific mutations only at predicted Neddylation sites (lysine residues) on the capsid proteins, while leaving the rest of the capsid structure intact. This localized modification approach prevents proteasomal degradation at critical sites without disrupting the overall capsid architecture, viral assembly, or gene delivery function, thus resolving the contradiction between improving transduction and maintaining structural stability
3Productivity
If site-directed mutagenesis is performed on multiple Neddylation sites, then transduction efficiency is significantly improved, but process complexity increases
Solution Approach 1:
The patent applies preliminary action by using bioinformatics tools (NeddyPreddy web server) to predict Neddylation sites on AAV capsid proteins before performing mutagenesis. This pre-identification of target sites (VP1-K33, VP1-K61, VP1-K490, VP1-K640, VP1-K665, and corresponding sites on VP2/VP3) streamlines the mutagenesis process, allowing systematic modification of multiple sites without excessive complexity, thereby achieving significant transduction improvement while managing process complexity
Data Source
AI summary
The present invention provides a process for producing a plurality of Neddylation site modified AAV vectors. In one embodiment, the process comprises predicting a plurality of Neddylation sites on AAV VP1 capsid protein sequence based on relatively high confidence targets, wherein the AAV VP1 capsid protein sequence being set forth in Protein ID-YP_680426.1; and producing the plurality of Neddylation site modified AAV vectors based on predicted plurality of neddylation sites on AAV VP1 capsid protein sequence. The present invention for the first time highlights the role of Neddylation during AAV infection and its impact on generating novel AAV vectors with improved efficiency for ocular and hepatic gene therapy.